Symbotic Inc.

Thank you for standing by and welcome to Symbiotic's first quarter fiscal 2024 financial results conference call. At this time, all participants are on a listen-only mode. After the speaker's presentations, there'll be a question and answer session. To ask a question at that time, please press star 111 on your telephone. Please be advised that today's call is being recorded. At this time, I'd like to turn the call over to Jeff Evanson, Vice President of Investor Relations. Please go ahead.

Thanks, Val. Hello, everyone. I'm Jeff Evanson, Symbiotics VP of Investor Relations. Our press release and discussion today will include forward-looking statements based on assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements, including as a result of the factors described in cautionary statements and risk factors in Symbiotics financial release and regulatory filings with the SEC, by which any forward-looking statements made during this call are qualified in their entirety. In addition, during this call, we will discuss certain financial measures that are not recognized under U.S. generally accepted accounting principles, which the SEC refers to as non-GAAP measures. We believe these non-GAAP measures assist management in planning, forecasting, and evaluating our business and financial performance, including allocating resources. Reconciliations of these non-GAAP measures to their most comparable reported GAAP measures are included in our financial press release, which is available in the investor relations section of our website and is on file with the SEC. These non-GAAP measures may not be comparable to measures used by other issuers. Today we'll provide guidance for the first quarter, including revenue and adjusted EBITDA. We're not providing guidance for net loss today, which is the most comparable GAAP financial measure to adjusted EBITDA. We're not able to provide reconciliations of adjusted EBITDA to GAAP financial measures because certain items required for such reconciliations are outside of our control and or cannot be reasonably predicted, such as provision for stock-based compensation. On today's call, we'll be joined by Rick Cohen, Symbiotics founder, chairman, and chief executive officer, and Carol Hibbard, Symbiotics chief financial officer. These executives will discuss our first quarter fiscal 24 results and our outlook, followed by a Q&A.

With that, I'll turn it over to Rick. Rick? Thank you, Jeff.